Trial · NCT05349721
Participant flow24
How many started, completed or left each group, period by period.
1 to 20 of 24
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part A (24 Weeks) | STARTED | Utreloxastat | 222 | |
| Part A (24 Weeks) | STARTED | Placebo | 114 | |
| Part A (24 Weeks) | Received at Least 1 Dose of Double-blind Study Drug in the Part A | Utreloxastat | 220 | |
| Part A (24 Weeks) | Received at Least 1 Dose of Double-blind Study Drug in the Part A | Placebo | 114 | |
| Part A (24 Weeks) | COMPLETED | Utreloxastat | 179 | |
| Part A (24 Weeks) | COMPLETED | Placebo | 100 | |
| Part A (24 Weeks) | NOT COMPLETED | Utreloxastat | 43 | |
| Part A (24 Weeks) | NOT COMPLETED | Placebo | 14 | |
| Part B (28 Weeks) | STARTED | Utreloxastat | 173 | |
| Part B (28 Weeks) | STARTED | Placebo | 100 | |
| Part B (28 Weeks) | Received at Least 1 Dose of Open-label Utreloxastat During Part B | Utreloxastat | 173 | |
| Part B (28 Weeks) | Received at Least 1 Dose of Open-label Utreloxastat During Part B | Placebo | 100 | |
| Part B (28 Weeks) | COMPLETED | Utreloxastat | 38 | |
| Part B (28 Weeks) | COMPLETED | Placebo | 27 | |
| Part B (28 Weeks) | NOT COMPLETED | Utreloxastat | 135 | |
| Part B (28 Weeks) | NOT COMPLETED | Placebo | 73 | |
| Part C (108 Weeks) | STARTED | Utreloxastat | 35 | |
| Part C (108 Weeks) | STARTED | Placebo | 27 | |
| Part C (108 Weeks) | Received at Least 1 Dose of Open-label Utreloxastat During Part C | Utreloxastat | 35 | |
| Part C (108 Weeks) | Received at Least 1 Dose of Open-label Utreloxastat During Part C | Placebo | 27 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05349721/flow